Skip to content. | Skip to navigation

Personal tools

This is SunRain Plone Theme


You are here: Home / Events / RINVIATO - Prof. Graziella Pellegrini: Regenerative Medicine from bench to beside: overcoming the challenges?

RINVIATO - Prof. Graziella Pellegrini: Regenerative Medicine from bench to beside: overcoming the challenges?

Centre for Regenerative Medicine "S. Ferrari” Department of Surgery, Medicine, Odontoiatry and Morphological Sciences University of Modena and Reggio Emilia Via Glauco Gottardi, 100 41125 - Modena (Italy)
When Mar 09, 2020
from 12:00 PM to 01:30 PM
Where CNR Conference Room
Contact Name
Contact Phone 081 6132 357
Add event to calendar vCal

Graziella Pellegrini received her master degrees in Chemistry and Pharmacy at the University of Genova and is founding member of the International Ocular Surface Society. Currently, she is full professors of Cell Biology and coordinators of Cell Therapy at the Centre for Regenerative Medicine of the University of Modena and Reggio Emilia. She is co-founder, member of the Board, and Director of Research & Development of Holostem Terapie Avanzate S.r.l., Modena, Italy.

Graziella has dedicated her scientific activities to translational medicine and have been a driving force in the development of epithelial stem cell-mediated cell and gene therapy. Following on early work on the use of human epidermal stem cell cultures in life-saving treatment of massive full-thickness burns and in repigmentation of stable vitiligo and piebaldism by keratinocyte/melanocyte co-colture, she established human urethral stem cell culture aimed at urethral regeneration in posterior hypospadias, with co-author De Luca. She has characterised molecular mechanisms of epithelial stem cells, leading to the use of limbal cultures for corneal regeneration in patients with blindness due to severe limbal stem cell deficiency. This treatment allows recovery of normal vision and received marketing authorization from the European Medicine Agency (Holoclar®). Graziella was also co-pioneering ex-vivo epidermal stem cell-mediated gene therapy for genetic skin diseases. The first successful clinical trial to treat junctional epidermolysis bullosa (JEB) was successfully concluded with life-saving regeneration of the entire functional epidermis on a 7-year-old child suffering from a life-threatening form of JEB. She received numerous awards, including the 2020 Louis Jeantet Award, 2018 ISSCR Innovation award (co-awarded), 2018 International Prize “Lombardia è ricerca”, (co-awarded), Italian Government Award “Le Ragioni della Nuova Politica” 2017, Prix Galien Award Netherlands 2016 and Prix Galien Award United Kingdom 2016 for Holoclar, MIT technology Review Italia “Smart & Disruptive Companies 2015” (co-awarded), Biennal Award “A.I.R.C.M.O.” (Italian Association for research and treatment of ocular pathologies) 2002 . She is authors of more than 100 publications and several international patents.

Filed under: